Harrow completed the acquisition of Melt Pharmaceuticals.

Harrow, a provider of ophthalmic disease management solutions, completed the acquisition of Melt Pharmaceuticals, a clinical-stage pharmaceutical company focused on non-opioid, non-IV therapies for sedation for medical procedures. Financial terms were not disclosed. “We’re incredibly excited about MELT-300’s potential to transform procedural sedation, reduce opioid exposure, and expand safe, accessible sedation options across medical specialties. It’s not just a scientific or commercial achievement — it’s a meaningful step forward for patients and for the US healthcare system," Mark L. Baum, Harrow CEO.